Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Celldex Therapeutics Inc shares valued at $121,210 were sold by Jimenez Freddy A. on Dec 04 ’25. At $29.09 per share, Jimenez Freddy A. sold 4,166 shares. The insider’s holdings dropped to 30,796 shares worth approximately $0.81 million following the completion of this transaction.
Also, FREDDY A JIMENEZ purchased 4,166 shares, netting a total of over 121,210 in proceeds.
Before that, Wright Richard M. had sold 49,298 shares from its account. In a trade valued at $1,183,177, the Former Officer traded Celldex Therapeutics Inc shares for $24.00 each. Upon closing the transaction, the insider’s holdings decreased to 49,298 shares, worth approximately $0.55 million.
As published in their initiating research note from Mizuho on October 21, 2025, Celldex Therapeutics Inc [CLDX] has been an Outperform and the price target has been revised to $48. Analysts at Barclays started covering the stock with ‘”an Underweight”‘ outlook in a report released in mid October. As of April 28, 2025, Canaccord Genuity has initiated its “Buy” rating for CLDX. Earlier on March 20, 2025, Morgan Stanley initiated its rating. Their recommendation was “an Overweight” for CLDX stock.
Analyzing CLDX Stock Performance
On last trading session, Celldex Therapeutics Inc [NASDAQ: CLDX] rose 1.58% to $26.34. The stock’s lowest price that day was $25.79, but it reached a high of $26.94 in the same session. During the last five days, there has been a drop of approximately -5.12%. Over the course of the year, Celldex Therapeutics Inc shares have jumped approximately 8.31%.
Is Celldex Therapeutics Inc subject to short interest?
Stocks of Celldex Therapeutics Inc saw a sharp steep in short interest on 2025-12-31 dropping by -0.43 million shares to 8.24 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 8.68 million shares. A decline of -5.23% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 10.59 of the overall float, the days-to-cover ratio (short ratio) decline to 10.59.
Which companies own the most shares of Celldex Therapeutics Inc (CLDX)?
In terms of Celldex Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 24 in the next 12 months, down nearly -7.44% from the previous closing price of $25.93. Analysts anticipate Celldex Therapeutics Inc stock to reach 24 by 2026, with the lowest price target being 24. In spite of this, 4 analysts ranked Celldex Therapeutics Inc stock as Buy at the end of 2026. On February 13, 2025, UBS assigned a price target of “a Buy” to the stock and initiated coverage with a $44.
